Logo image of HHS

HARTE-HANKS INC (HHS) Stock Fundamental Analysis

NASDAQ:HHS - Nasdaq - US4161962026 - Common Stock - Currency: USD

5.05  -0.14 (-2.7%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to HHS. HHS was compared to 93 industry peers in the Media industry. The financial health of HHS is average, but there are quite some concerns on its profitability. HHS has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

HHS had positive earnings in the past year.
HHS had a negative operating cash flow in the past year.
In multiple years HHS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: HHS reported negative operating cash flow in multiple years.
HHS Yearly Net Income VS EBIT VS OCF VS FCFHHS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -27.60%, HHS is not doing good in the industry: 87.36% of the companies in the same industry are doing better.
The Return On Equity of HHS (-141.76%) is worse than 83.91% of its industry peers.
HHS's Return On Invested Capital of 10.18% is amongst the best of the industry. HHS outperforms 88.51% of its industry peers.
HHS had an Average Return On Invested Capital over the past 3 years of 14.02%. This is significantly above the industry average of 7.01%.
Industry RankSector Rank
ROA -27.6%
ROE -141.76%
ROIC 10.18%
ROA(3y)13.3%
ROA(5y)2.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)14.02%
ROIC(5y)N/A
HHS Yearly ROA, ROE, ROICHHS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

With a Operating Margin value of 4.89%, HHS perfoms like the industry average, outperforming 45.98% of the companies in the same industry.
The Gross Margin of HHS (18.72%) is worse than 81.61% of its industry peers.
In the last couple of years the Gross Margin of HHS has grown nicely.
Industry RankSector Rank
OM 4.89%
PM (TTM) N/A
GM 18.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y19.74%
HHS Yearly Profit, Operating, Gross MarginsHHS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HHS is creating some value.
The number of shares outstanding for HHS has been reduced compared to 1 year ago.
The number of shares outstanding for HHS has been increased compared to 5 years ago.
HHS has a better debt/assets ratio than last year.
HHS Yearly Shares OutstandingHHS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
HHS Yearly Total Debt VS Total AssetsHHS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 13.03 indicates that HHS is not in any danger for bankruptcy at the moment.
HHS's Altman-Z score of 13.03 is amongst the best of the industry. HHS outperforms 98.85% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that HHS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, HHS belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 13.03
ROIC/WACC1.07
WACC9.55%
HHS Yearly LT Debt VS Equity VS FCFHHS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.46 indicates that HHS should not have too much problems paying its short term obligations.
HHS's Current ratio of 1.46 is in line compared to the rest of the industry. HHS outperforms 49.43% of its industry peers.
A Quick Ratio of 1.46 indicates that HHS should not have too much problems paying its short term obligations.
HHS's Quick ratio of 1.46 is in line compared to the rest of the industry. HHS outperforms 50.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 1.46
HHS Yearly Current Assets VS Current LiabilitesHHS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

HHS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.55%.
The Revenue has decreased by -4.67% in the past year.
HHS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.62% yearly.
EPS 1Y (TTM)-30.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-4.67%
Revenue growth 3Y2.68%
Revenue growth 5Y-7.62%
Sales Q2Q%1.08%

3.2 Future

Based on estimates for the next years, HHS will show a very strong growth in Earnings Per Share. The EPS will grow by 40.18% on average per year.
HHS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.68% yearly.
EPS Next Y-729.87%
EPS Next 2Y40.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.64%
Revenue Next 2Y1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HHS Yearly Revenue VS EstimatesHHS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
HHS Yearly EPS VS EstimatesHHS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 2.64, the valuation of HHS can be described as very cheap.
96.55% of the companies in the same industry are more expensive than HHS, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of HHS to the average of the S&P500 Index (29.63), we can say HHS is valued rather cheaply.
HHS is valuated cheaply with a Price/Forward Earnings ratio of 4.67.
Based on the Price/Forward Earnings ratio, HHS is valued cheaper than 97.70% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.68. HHS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 2.64
Fwd PE 4.67
HHS Price Earnings VS Forward Price EarningsHHS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

95.40% of the companies in the same industry are more expensive than HHS, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.33
HHS Per share dataHHS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

HHS's earnings are expected to grow with 40.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.18%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

HHS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARTE-HANKS INC

NASDAQ:HHS (2/21/2025, 8:25:34 PM)

5.05

-0.14 (-2.7%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners34.85%
Inst Owner Change-8.14%
Ins Owners9.01%
Ins Owner Change4.52%
Market Cap36.81M
Analysts80
Price Target17.85 (253.47%)
Short Float %0.58%
Short Ratio1.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1305.94%
Min EPS beat(2)-80.2%
Max EPS beat(2)2692.08%
EPS beat(4)3
Avg EPS beat(4)743.73%
Min EPS beat(4)-80.2%
Max EPS beat(4)2692.08%
EPS beat(8)4
Avg EPS beat(8)659.83%
EPS beat(12)8
Avg EPS beat(12)512.59%
EPS beat(16)10
Avg EPS beat(16)460.86%
Revenue beat(2)0
Avg Revenue beat(2)-3.11%
Min Revenue beat(2)-6.13%
Max Revenue beat(2)-0.09%
Revenue beat(4)1
Avg Revenue beat(4)-0.55%
Min Revenue beat(4)-6.13%
Max Revenue beat(4)4.26%
Revenue beat(8)2
Avg Revenue beat(8)-1.45%
Revenue beat(12)5
Avg Revenue beat(12)0.34%
Revenue beat(16)9
Avg Revenue beat(16)1.74%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.64
Fwd PE 4.67
P/S 0.2
P/FCF N/A
P/OCF N/A
P/B 1.75
P/tB 2.19
EV/EBITDA 2.33
EPS(TTM)1.91
EY37.82%
EPS(NY)1.08
Fwd EY21.4%
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.36
OCFYN/A
SpS25.73
BVpS2.89
TBVpS2.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.6%
ROE -141.76%
ROCE 12.88%
ROIC 10.18%
ROICexc 11.11%
ROICexgc 11.87%
OM 4.89%
PM (TTM) N/A
GM 18.72%
FCFM N/A
ROA(3y)13.3%
ROA(5y)2.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)14.02%
ROIC(5y)N/A
ROICexc(3y)17.14%
ROICexc(5y)N/A
ROICexgc(3y)17.53%
ROICexgc(5y)N/A
ROCE(3y)17.75%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.49%
GM growth 5Y19.74%
F-Score3
Asset Turnover1.74
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 104.41%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 1.46
Altman-Z 13.03
F-Score3
WACC9.55%
ROIC/WACC1.07
Cap/Depr(3y)132.19%
Cap/Depr(5y)105.26%
Cap/Sales(3y)1.94%
Cap/Sales(5y)1.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-729.87%
EPS Next 2Y40.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.67%
Revenue growth 3Y2.68%
Revenue growth 5Y-7.62%
Sales Q2Q%1.08%
Revenue Next Year-0.64%
Revenue Next 2Y1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.02%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.06%
OCF growth 3YN/A
OCF growth 5YN/A